Agentless security for untouchable IoT devices

Tern plc

The rapid expansion of connected devices across enterprise and industrial environments presents a pressing security challenge for organisations preparing for 2026 and beyond. Increasingly, a large portion of a company’s device estate cannot be secured through traditional software agents or conventional update mechanisms. Many sensors, embedded controllers, medical instruments and legacy systems are either incapable of running additional software, cannot tolerate downtime for patching, or are geographically dispersed in remote or hostile environments.

Conventional endpoint security, built on the assumption that every device can host a monitoring agent, struggles at scale in environments where devices are resource constrained or run proprietary firmware. Attempting to retrofit traditional security tools often results in blind spots across thousands of device types from hundreds of vendors, increasing attack surface and operational complexity.

Agentless IoT security reframes this problem by decoupling protection from the devices themselves. Instead of installing security software on each endpoint, agentless solutions observe devices from the outside. They use network traffic analysis, infrastructure logs and application interfaces to discover and classify every IP‑connected device. By doing so, organisations gain visibility into assets they did not even know existed. This inventory of devices and behaviours becomes the foundation for identity‑based controls and policy enforcement that can be applied without touching the device itself.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

Search